Some NMDA receptor antagonists selective for GluN2B subunit receptors have shown antiparkinsonian activity in MPTP-lesioned primates, either when used alone or in combination with levodopa [150], and reduce dyskinesias induced by levodopa [151,151]; CP-101,606, an NMDA receptor antagonist selective for GluN2B, has shown the ability to prevent the onset of motor response abnormalities induced by levodopa in Parkinsonian rats, as well as improve these motor deficits after they have developed. Here, GRIN2B is linked to Dyskinesia.